m6A-induced LINC00958 promotes breast cancer tumorigenesis via the miR-378a-3p/YY1 axis-Reference-Cited by-同舟云学术

m6A-induced LINC00958 promotes breast cancer tumorigenesis via the miR-378a-3p/YY1 axis

Published:2021-02-02 Issue:1 Volume:7 Page:
ISSN:2058-7716
Container-title:Cell Death Discovery
language:en
Short-container-title:Cell Death Discov.

Author:

Rong Dongwen,Dong Qian,Qu Huajun,Deng Xinna,Gao Fei,Li Qingxia,Sun Ping

Abstract

AbstractIncreasing evidence demonstrates that long noncoding RNAs (lncRNAs) play critical roles in human breast cancer (BC) tumorigenesis. However, the mechanisms by which lncRNA and N6-methyladenosine (m6A) regulate BC tumorigenesis are still unclear. In the present research, LINC00958 was markedly overexpressed in BC tissue and cells, and LINC00958 upregulation promoted the tumor progression of BC cells. Mechanistically, m6A methyltransferase-like 3 (METTL3) gave rise to the upregulation of LINC00958 by promoting its RNA transcript stability. Moreover, LINC00958 acted as a competitive endogenous RNA for miR-378a-3p to promote YY1. Overall, these data provide novel insight into how m6A-mediated LINC00958 regulates BC tumorigenesis.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/s41420-020-00382-z.pdf

Reference25 articles.

1. Aydin, H. et al. Radiologic findings of a rare subtype of invasive breast cancer with poor prognosis: metaplastic carcinoma of the breast. Curr. Med. Imaging Rev. 15, 338–348 (2019).

2. Baxevanis, C. N., Fortis, S. P. & Perez, S. A. The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies. Semin. Cancer Biol. https://doi.org/10.1016/j.semcancer.2019.12.018 (2019).

3. Cai, X. et al. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 415, 11–19 (2018).

4. Fan, H. et al. LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression. Biomed. Pharmacother. 125, 109987 (2020).

5. Mahtani, R. et al. A roundtable discussion of the Breast Cancer Therapy Expert Group (BCTEG): clinical developments and practice guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer. Clin. Breast Cancer https://doi.org/10.1016/j.clbc.2019.08.001 (2019).

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory effect of N6-methyladenosine on tumor angiogenesis;Frontiers in Immunology;2024-09-04

2. Functions of methyltransferase-like 3 in breast cancer: pathogenesis, drug resistance, and therapeutic target;Breast Cancer Research;2024-07-03

3. A Novel ceRNET Relying on the lncRNA JPX, miR-378a-3p, and Its mRNA Targets in Lung Cancer;Cancers;2024-04-17

4. Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A‐to‐I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs;Cell Biochemistry and Function;2024-04

5. Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response;Non-coding RNA Research;2024-03